

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Vosaroxin for treating relapsed or refractory acute myeloid leukaemia

Batch 46

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No equality issues were raised during consultation. The scoping workshop attendees noted that the European Medicines Agency has accepted the marketing authorisation application as a treatment for 'relapsed/refractory AML in patients aged 60 years and older'.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Attendees at the scoping workshop understood that NICE guidance will only be issued in accordance with the marketing authorisation. However considering NICE's obligations towards people protected by the equality legislation; it was decided that age restriction should not be specified in the remit or the scope at this stage.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

Approved by Associate Director (name): Melinda Goodall

Date: 19/10/2016